Based on polymerase chain response technology.

Abbott and GSK to Collaborate on Molecular Diagnostic Check Abbott has entered into an agreement with GlaxoSmithKline to build up an automated molecular diagnostic test, based on polymerase chain response technology, designed to screen non-little cell lung cancers tumors for expression of the MAGE-A3 antigen. GSK’s MAGE-A3 ASCI applicant is currently being evaluated as an adjuvant treatment in resected NSCLC in the Stage III clinical study MAGRIT, the largest lung cancer treatment study ever conducted rx online . To meet the requirements to get GSK’s MAGE A3 ASCI, patients will need to have MAGE-A3 expressing NSCLC tumors. MAGE-A3 can be a tumor-specific antigen that’s expressed in non-small cell lung malignancy and a wide variety of other cancers, however, not in regular cells.

‘We’re very happy to be collaborating with the CHAI in its proactive outreach effort to check infants in developing countries for HIV,’ stated Stafford O’Kelly, head of Abbott’s molecular diagnostics business.’.. Abbott, CHAI enter contract to provide HIV testing to infants Abbott and the Clinton Health Gain access to Initiative possess joined forces to supply HIV tests to infants in all countries working in partnership with the CHAI. Under conditions of the agreement, Abbott shall supply its RealTime HIV-1 Qualitative test kits to healthcare facilities. As well as the supply of HIV assessments and DBS sample collection for research use, Abbott is normally collaborating with CHAI to build up a ‘turn-key’ laboratory answer, including training protocols on instruments that will be used to establish completely functioning molecular diagnostic laboratories in areas where such facilities usually do not presently exist.